Liglimet 2.5/850mg Tablet 6pcs

Uses of Liglimet 2.5/850mg Tablet

• Used to manage type II diabetes mellitus in adults

Overdose Effects of Liglimet 2.5/850mg Tablet

• Supportive measures should be taken in case of overdose. Linagliptin is not likely removable by dialysis, but Metformin is dialyzable.
• Clinical trials with high doses of Linagliptin showed no dose-related adverse effects.
• Large doses of Metformin (>50 grams) have resulted in hypoglycemia and lactic acidosis.

Side Effects of Liglimet 2.5/850mg Tablet

Common side effects include nasopharyngitis and diarrhea. Hypoglycemia is more frequent in patients taking Liglimet along with sulfonylureas.

Quick Suggestions:

• Liglimet 2.5/850mg Tablet should be taken with food to lower the chances of having an upset stomach.
• Take Liglimet 2.5/850mg Tablet in addition to regular exercise and a healthy diet to lower the levels of blood sugar.
• Chances of weight gain and low blood sugar are lesser as compared to other diabetes medicines.
• Hypoglycemia (low blood sugar level) may occur when taken along with other antidiabetic medicines, alcohol, or on delaying/skipping a meal. Carry a sugar source with you for immediate relief.
• Monitor your blood sugar level regularly while you are taking this medicine.
• Inform your doctor about your diabetes treatment if you are due to have any surgery under a general anesthetic.
• Tell your doctor immediately if you experience any deep or rapid breathing, persistent nausea, vomiting, or stomach pain as Metformin + Linagliptin may cause a rare but serious condition called lactic acidosis, which is an excess of lactic acid in the blood.

Indication of Liglimet 2.5/850mg Tablet

Liglimet 2.5/850mg Tablet is used alongside diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is suitable.

Pharmacology

• Linagliptin: Used to improve glycemic control in type 2 diabetes patients by inhibiting DPP-4 (dipeptidyl peptidase-4), which degrades incretin hormones (GLP-1 and GIP). This results in increased levels of active incretin hormones, promoting insulin release from pancreatic beta cells and reducing glucagon secretion from alpha cells.
• Metformin Hydrochloride: An oral antihyperglycemic drug (biguanide class) used for managing type 2 diabetes by lowering both basal and postprandial plasma glucose. Unlike sulfonylureas, it doesn’t cause hypoglycemia. Metformin decreases liver glucose production, reduces intestinal glucose absorption, and enhances insulin sensitivity by increasing peripheral glucose uptake and utilization.

Dosage & Administration of Liglimet 2.5/850mg Tablet

Immediate Release Tablets:

• The dosage should be personalized based on effectiveness and tolerability.
• Maximum recommended dose: 2.5 mg of Linagliptin and 1000 mg of Metformin Hydrochloride twice daily with meals.
• Start with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily for patients not previously treated with Metformin.
• For those already on Metformin, begin with 2.5 mg Linagliptin and their current Metformin dose twice daily.
• Patients already on separate Linagliptin and Metformin can switch to this combination with equivalent doses.

Extended-Release Tablets:

• Dosage should be personalized, not exceeding 5 mg of Linagliptin and 2000 mg of Metformin Hydrochloride daily.
• Start with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal for those not previously on Metformin.
• For those already on Metformin, start with 5 mg Linagliptin daily and an equivalent Metformin dose once daily.
• Patients on immediate-release tablets can switch to extended-release tablets containing 5 mg Linagliptin and an equivalent Metformin dose once daily.
• Extended-release tablets of 5 mg Linagliptin/1000 mg Metformin should be taken as a single tablet once daily, or two 2.5 mg Linagliptin/1000 mg Metformin tablets together once daily.

Interaction

• Cationic Drugs: Drugs such as amiloride, digoxin, morphine, and others that are excreted via renal tubular secretion might interact with Metformin. Monitor patients carefully and adjust doses if necessary.
• Carbonic Anhydrase Inhibitors: Drugs like topiramate may induce metabolic acidosis, increasing the risk of lactic acidosis. Use with caution.
• P-glycoprotein and CYP3A4 Enzyme Inducers: Rifampin and similar drugs may reduce Linagliptin’s efficacy. Consider alternative treatments if strong inducers are necessary.
• Drugs Affecting Glycemic Control: Thiazides, corticosteroids, and other drugs may cause hyperglycemia. Monitor and adjust treatment as needed when these drugs are added or withdrawn.

Contraindications

• Not recommended for patients with renal impairment due to the risk of Metformin accumulation and lactic acidosis.
• Contraindicated in patients with acute or chronic metabolic acidosis and those hypersensitive to Linagliptin or Metformin.

Pregnancy & Lactation

There are no adequate studies in pregnant women, so use only if clearly needed. Use caution when administering to breastfeeding mothers.

Precautions & Warnings

• Discontinue Metformin if lactic acidosis occurs and provide supportive therapy.
• Discontinue if pancreatitis is suspected.
• Temporarily stop for surgical procedures or diagnostic tests requiring contrast dye.
• Monitor hematologic parameters annually due to potential Vitamin B12 deficiency.
• Be aware of lactic acidosis symptoms and take precautions during physical exertion or illness.
• Hypoglycemia risks: manage symptoms early and avoid alcohol.

Storage Conditions:

Store in a cool, dry place below 30°C, away from light and moisture, and keep out of reach of children.